OncoSec receives $7 million investment from Alpha Holdings at $1.50 per share
OncoSec Medical announced the Company has received a $7.0 million investment at $1.50 per share from Alpha Holdings as part of a strategic investment centered on the clinical development of OncoSec's lead immunotherapy product candidate, TAVO(TM) (tavokinogene telseplasmid). December 10, 2018